Michael Bolinder
Chief Executive Officer at ACACIA PHARMA GROUP PLC
Profile
Michael Bolinder is the CEO of Acacia Pharma Group Ltd.
since 2019.
Prior to this, he worked as Head of Marketing & Commercial Strategy at Mallinckrodt Pharmaceuticals Ltd.
from 2013 to 2015.
He completed his undergraduate degree from Florida State University.
Michael Bolinder active positions
| Companies | Position | Start |
|---|---|---|
| ACACIA PHARMA GROUP PLC | Chief Executive Officer | 2019-07-31 |
Former positions of Michael Bolinder
| Companies | Position | End |
|---|---|---|
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. | Sales & Marketing | 2015-07-31 |
Training of Michael Bolinder
| Florida State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Acacia Pharma Group Ltd.
 Acacia Pharma Group Ltd. Pharmaceuticals: OtherHealth Technology Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom. | Health Technology |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. | Health Technology |
- Stock Market
- Insiders
- Michael Bolinder
